Loading...

IQVIA Holdings Inc.

0JDM.LLSE
Healthcare
Medical - Pharmaceuticals
£190.60
£-0.22(-0.12%)

IQVIA Holdings Inc. (0JDM.L) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for IQVIA Holdings Inc. (0JDM.L), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
2.81%
2.81%
Operating Income Growth
11.38%
11.38%
Net Income Growth
1.10%
1.10%
Operating Cash Flow Growth
26.38%
26.38%
Operating Margin
13.87%
13.87%
Gross Margin
34.25%
34.25%
Net Profit Margin
7.88%
7.88%
ROE
19.96%
19.96%
ROIC
10.34%
10.34%

IQVIA Holdings Inc. (0JDM.L) Income Statement & Financial Overview

Analyze IQVIA Holdings Inc.’s 0JDM.L earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$3.83B$3.96B$3.90B$3.81B
Cost of Revenue$2.53B$2.58B$2.52B$2.49B
Gross Profit$1.30B$1.38B$1.38B$1.33B
Gross Profit Ratio$0.34$0.35$0.35$0.35
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$508.00M$453.00M$522.00M$509.00M
Operating Expenses$802.00M$752.00M$828.00M$509.00M
Total Costs & Expenses$3.33B$3.33B$3.35B$3.27B
Interest Income$11.00M$11.00M$13.00M$12.00M
Interest Expense$165.00M$171.00M$170.00M$163.00M
Depreciation & Amortization$265.00M$303.00M$278.00M$269.00M
EBITDA$753.00M$1.02B$805.00M$817.00M
EBITDA Ratio$0.20$0.26$0.21$0.21
Operating Income$496.00M$580.00M$550.00M$520.00M
Operating Income Ratio$0.13$0.15$0.14$0.14
Other Income/Expenses (Net)-$173.00M-$36.00M-$201.00M-$84.00M
Income Before Tax$323.00M$544.00M$349.00M$436.00M
Income Before Tax Ratio$0.08$0.14$0.09$0.11
Income Tax Expense$61.00M$112.00M$65.00M$75.00M
Net Income$249.00M$437.00M$285.00M$363.00M
Net Income Ratio$0.07$0.11$0.07$0.10
EPS$1.42$2.44$1.57$1.99
Diluted EPS$1.40$2.42$1.55$1.97
Weighted Avg Shares Outstanding$175.70M$178.90M$182.10M$182.20M
Weighted Avg Shares Outstanding (Diluted)$177.40M$180.80M$184.20M$184.30M

Over the past four quarters, IQVIA Holdings Inc. demonstrated steady revenue growth, increasing from $3.81B in Q2 2024 to $3.83B in Q1 2025. Operating income reached $496.00M in Q1 2025, maintaining a consistent 13% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $753.00M, reflecting operational efficiency. Net income dropped to $249.00M, with EPS at $1.42. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;